Paper
Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease
Published Aug 1, 2008 · S. Pallotta, F. Pace, S. Marelli
Expert Review of Gastroenterology & Hepatology
11
Citations
0
Influential Citations
Abstract
Rabeprazole is a proton pump inhibitor (PPI) presenting a very advantageous pharmacodynamic and pharmacokinetic profile over older PPIs. In particular, this drug has a very fast onset of action, due to a short activation time and a very high pKa, and may therefore be defined as a ‘second generation’ PPI. The aim of this article is to provide an update on the pharmacology and clinical profile of rabeprazole and its use in acid-related disorders, with a particular focus on its role in gastroesophageal reflux disease; in the treatment and prevention of duodenal and gastric ulcers and Zollinger–Ellison syndrome; in the therapy of the extraesophageal manifestations of gastroesophageal reflux disease (in particular the respiratory and ear, nose and throat ones); and in the eradication of Helicobacter pylori.
Rabeprazole is a second-generation proton pump inhibitor with a fast onset of action and favorable pharmacodynamic and pharmacokinetic profile, effectively treating acid-related disorders and preventing complications.
Full text analysis coming soon...